SCHEMBL12378964

SCHEMBL12378964

Cc1ccc(NC(=O)CSc2nnc(C(F)(F)F)n2-c2ccc(C3CC3)c3ccccc23)c(C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.49
ALDH1A1 P00352 2/20 0.49
MAPT P10636 1/20 0.49
SLC22A12 Q96S37 7/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
SLC22A11 Q9NSA0 1/20 0.49
KMT2A Q03164 1/20 0.49
SLC2A9 Q9NRM0 2/20 0.48
TSHR P16473 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
TP53 P04637 3/20 0.46
GAA P10253 1/20 0.44
LMNA P02545 1/20 0.43
CCR5 P51681 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL879231 0.93 SLC22A12 (0.49) THRBALDH1A1MAPTSLC22A12CYP2C9
SCHEMBL10029331 0.92 SLC22A12 (0.49) THRBALDH1A1MAPTSLC22A12CYP2C9
SCHEMBL12010037 0.89 SLC22A12 (0.53) THRBALDH1A1MAPTSLC22A12CYP2C9
SCHEMBL10227725 0.81 SLC22A12 (0.73) ALDH1A1SLC22A12CYP2C9CYP2C19CYP1A2
SCHEMBL10029207 0.81 SLC22A12 (0.53) THRBALDH1A1MAPTSLC22A12CYP2C9
SCHEMBL12056187 0.80 SLC22A12 (0.64) THRBALDH1A1MAPTSLC22A12CYP2C9
SCHEMBL1719573 0.79 SLC22A12 (0.65) THRBALDH1A1MAPTSLC22A12CYP2C9
SCHEMBL253614 0.79 SLC22A12 (0.62) THRBALDH1A1MAPTSLC22A12CYP2C9
SCHEMBL249261 0.78 SLC22A12 (0.66) SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4
SCHEMBL10029197 0.75 SLC22A12 (0.51) ALDH1A1SLC22A12CYP2C9CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003681-B2 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester ARDEA BIOSCIENCES, INC. (US) 2011-08-23 US disclosed
US-20100267724-A2 S-TRIAZOLE ALPHA-MERCAPTOACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE ARDEA BIOSCIENCES, INC. (US) 2010-10-21 US disclosed
US-20100081827-A1 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER ARDEA BIOSCIENCES, INC. (US) 2010-04-01 US disclosed
US-20100069645-A1 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER ARDEA BIOSCIENCES, INC. 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069645-A1 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER GRHPR, POLR2H, ME2 THRB 1350/4885ALDH1A1 1839/4885MAPT 2892/4885
US-20100267724-A2 S-TRIAZOLE ALPHA-MERCAPTOACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE SPR, POLR2H, QTRT1 THRB 1320/4885ALDH1A1 1135/4885MAPT 2695/4885
US-20100081827-A1 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER GRHPR, POLR2H, DECR1 THRB 1407/4885ALDH1A1 1632/4885MAPT 2903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.